Kenpaullone | Enzo Life Sciences BML-EI310-0005 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Kenpaullone

catalog :

BML-EI310-0005

quantity :

5 mg

citations: 10

Reference
Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J. 2003;371:199-204 pubmed
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb J, Snyder G, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J Biol Chem. 2001;276:251-60 pubmed
Leost M, Schultz C, Link A, Wu Y, Biernat J, Mandelkow E, et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem. 2000;267:5983-94 pubmed
Sausville E, Johnson J, Alley M, Zaharevitz D, Senderowicz A. Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci. 2000;910:207-21; discussion 221-2 pubmed
Gussio R, Zaharevitz D, McGrath C, Pattabiraman N, Kellogg G, Schultz C, et al. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des. 2000;15:53-66 pubmed
Kunick C, Schultz C, Lemcke T, Zaharevitz D, Gussio R, Jalluri R, et al. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg Med Chem Lett. 2000;10:567-9 pubmed
Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem. 1999;6:859-75 pubmed
Schultz C, Link A, Leost M, Zaharevitz D, Gussio R, Sausville E, et al. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem. 1999;42:2909-19 pubmed
Zaharevitz D, Gussio R, Leost M, Senderowicz A, Lahusen T, Kunick C, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999;59:2566-9 pubmed
Kunick C. Fused azepinones with antitumor activity. Curr Pharm Des. 1999;5:181-94 pubmed

product information

Product ID :

BML-EI310

Catalog Number :

BML-EI310-0005

Product Name :

Kenpaullone

Product Type :

Biochemical

Size :

5 mg

list of Pubmed id :

12534346, 11013232, 10998059, 10911915, 10888036, 10741555, 10495356, 10425100, 10363974, 10066889

Product Description :

Potent inhibitor of CDK1/cyclin B (IC50=400nM). Also inhibits CDK2/cyclin A (IC50=680nM) , CDK5 (IC50=850nM) and with much less effect other kinases. More recently, kenpaullone has been found to be a useful GSK-3β inhibitor (IC50=23nM). Induces pluripotency in somatic cells when used in combination with reprogramming factors. Increases neurogenesis of human neural progenitor cells through stimulation of Wnt/β-catenin signaling pathway.

ALTnames :

9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5H)-one

Purity :

≥98% (TLC)

Storage :

-20°C